Michael Morris, MD
Medical Oncology · New York, NYNPI 1255302055
Payments from drug & device makers
Across 341 payments — averaging $89,258 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$26.2M
- Janssen Research & Development, LLC$2M
- Bristol Myers Squibb$1.2M
- Corcept Therapeutics$312K
- Progenics Pharmaceuticals, Inc.$207K
- F. Hoffmann-la Roche AG$199K
- plus $352K from 20 others
Across 19 payments — averaging $963.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10K
- Novartis Pharma AG$7K
- AbbVie$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 62 | $26,158,606 |
| Janssen Research & Development, LLC | 59 | $2,036,013 |
| Bristol Myers Squibb | 24 | $1,172,661 |
| Corcept Therapeutics | 33 | $312,175 |
| Progenics Pharmaceuticals, Inc. | 18 | $206,571 |
| F. Hoffmann-la Roche AG | 9 | $199,270 |
| Novartis | 9 | $179,288 |
| Astellas Pharma Global Development | 19 | $79,597 |
| E.r. Squibb & Sons, L.L.C. | 16 | $18,923 |
| Pfizer | 8 | $16,601 |
| Blue Earth Diagnostics | 5 | $10,500 |
| AbbVie | 13 | $7,958 |
| Daiichi Sankyo Inc. | 7 | $7,762 |
| Amgen | 13 | $6,873 |
| Lantheus Medical Imaging, Inc. | 3 | $5,028 |
| Exelixis Inc. | 3 | $3,989 |
| Advanced Accelerator Applications | 3 | $3,347 |
| Telix Pharmaceuticals | 4 | $2,803 |
| Curium US LLC | 2 | $2,713 |
| AstraZeneca | 16 | $2,458 |
| GSK | 1 | $2,400 |
| Janssen Global Services, LLC | 5 | $653 |
| Johnson & Johnson | 5 | $489 |
| Sanofi | 2 | $287 |
| Roche Products Limited | 1 | $53 |
| Myovant Sciences Inc. | 1 | $12 |
How this compares
$30,437,029 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New York
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
- Amy TierstenNew York$17.6M
- Rona YaegerNew York$17.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.